City

Clinical trials near Hamilton, Canada

Active studies with a listed research site in Hamilton, Canada.

36active studies

16recruiting now

34countries represented

1,498largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

Obesity, Weight GainCondition

Tirzepatide, PlaceboTreatment

Argentina, Australia69 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06439277See eligibility →

Recruiting nowPhase 3

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Obesity, Overweight and/or ObesityCondition

PF-08653944, PlaceboTreatment

Brazil, Canada50 locations

PfizerSponsor

Updated 2026-09-04 · NCT07595549See eligibility →

Recruiting nowPhase 2

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

Obesity, OverweightCondition

BI 3034701, Placebo matching BI 3034701Treatment

Australia, Canada54 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07662122See eligibility →

Recruiting nowPhase 3

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

Obesity or OverweightCondition

AZD6234, PlaceboTreatment

Argentina, Australia212 locations

AstraZenecaSponsor

Updated 2026-08-25 · NCT07784725See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Obesity, OverweightCondition

Eloralintide, PlaceboTreatment

Argentina, Australia162 locations

Eli Lilly and CompanySponsor

Updated 2026-08-21 · NCT07321886See eligibility →

Recruiting nowPhase 2

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Type 2 DiabetesCondition

LY3457263, PlaceboTreatment

Canada, Germany60 locations

Eli Lilly and CompanySponsor

Updated 2026-08-21 · NCT06897475See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

Obesity or OverweightCondition

Placebo, EnicepatideTreatment

Argentina, Australia195 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351045See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil57 locations

AmgenSponsor

Updated 2026-08-14 · NCT07226765See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Obesity, Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil61 locations

AmgenSponsor

Updated 2026-08-04 · NCT07225686See eligibility →

Recruiting nowPhase 3

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

Weight ManagementCondition

Elecoglipron, PlaceboTreatment

Argentina, Australia321 locations

AstraZenecaSponsor

Updated 2026-07-10 · NCT07667803See eligibility →

Recruiting nowPhase 3

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Obesity, Knee Osteoarthritis (OA)Condition

NNC0487-0111, Placebo (matched to NNC0487-0111 )Treatment

Australia, Bulgaria82 locations

Novo Nordisk A/SSponsor

Updated 2026-07-09 · NCT07481630See eligibility →

Recruiting nowNot applicable

Evaluation of Food Additive Contributions to Obesity: Pilot Study 1

Obesity (Disorder)Condition

Potassium sorbate one-time administration followed by washout then placebo one-time administration, Placebo one-time administration followed by washout then potassium sorbate one-time administrationTreatment

Canada1 locations

McMaster UniversitySponsor

Updated 2026-02-27 · NCT07437430See eligibility →

Recruiting nowPhase 4

JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity

Obesity (Disorder)Condition

Semaglutide Pen Injector, Behavioural Lifestyle Program (BLP)Treatment

Canada1 locations

McMaster UniversitySponsor

Updated 2026-01-14 · NCT06852391See eligibility →

Recruiting nowNot applicable

Dialectal Behaviour Therapy to Enhance Health Behaviour Change for Adolescents Living With Obesity (DIRECTION Trial)

Prevention, Type2DiabetesCondition

Dialectical behavioral therapy, LifestyleTreatment

Canada3 locations

University of ManitobaSponsor

Updated 2025-10-07 · NCT05338944See eligibility →

Recruiting nowPhase 4

Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

Prostate CancerCondition

Semaglutide Pen InjectorTreatment

Canada1 locations

Hamilton Health Sciences CorporationSponsor

Updated 2025-07-29 · NCT06908694See eligibility →

Recruiting nowNot applicable

SCORE! ACTIVE Trial

Chronic Disease, Childhood ObesityCondition

Physical activity program, NavigationTreatment

Canada1 locations

Hamilton Health Sciences CorporationSponsor

Updated 2025-02-25 · NCT06844786See eligibility →

Opening soonPhase 3

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Obesity or Overweight, Diabetes Mellitus, Type 2Condition

AZD6234, PlaceboTreatment

Argentina, Australia218 locations

AstraZenecaSponsor

Updated 2026-08-25 · NCT07784270See eligibility →

Opening soonPhase 3

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

Obesity or Overweight, Weight-Related ComorbidityCondition

AZD6234, PlaceboTreatment

Argentina, Brazil88 locations

AstraZenecaSponsor

Updated 2026-08-20 · NCT07776509See eligibility →

Opening soonPhase 3

Tirzepatide in the Treatment of Cannabis Use Disorder

Cannabis Use Disorder, Moderate, Cannabis Use Disorder, SevereCondition

TirzepatideTreatment

Canada1 locations

McMaster UniversitySponsor

Updated 2026-07-01 · NCT07671248See eligibility →

Active, not recruitingPhase 3

A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

Obesity, Overweight and/or ObesityCondition

PF-08653944, PlaceboTreatment

Argentina, Bulgaria188 locations

PfizerSponsor

Updated 2026-09-08 · NCT07400653See eligibility →

Active, not recruitingPhase 3

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

Obesity and OverweightCondition

MET097, PlaceboTreatment

Bulgaria, Canada169 locations

PfizerSponsor

Updated 2026-09-04 · NCT07311850See eligibility →

Active, not recruitingPhase 3

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

Overweight, ObesityCondition

Cagrilintide, Placebo (matched to Cagrilintide)Treatment

Argentina, Canada67 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07220759See eligibility →

Active, not recruitingPhase 3

Breast Cancer WEight Loss Study (BWEL Study)

Breast Ductal Carcinoma In Situ, Invasive Breast CarcinomaCondition

Health Education Program, Weight Loss InterventionTreatment

Canada, Guam1,498 locations

Alliance for Clinical Trials in OncologySponsor

Updated 2026-09-02 · NCT02750826See eligibility →

Active, not recruitingPhase 3

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

ObesityCondition

Cagrilintide, SemaglutideTreatment

Argentina, Australia256 locations

Novo Nordisk A/SSponsor

Updated 2026-08-31 · NCT05567796See eligibility →

Active, not recruitingPhase 1, Phase 2

A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight

Overweight and ObesityCondition

AZD9550, placeboTreatment

Austria, Canada15 locations

AstraZenecaSponsor

Updated 2026-08-26 · NCT06151964See eligibility →

Active, not recruitingPhase 3

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

Obesity, OverweightCondition

Cagrilintide, PlaceboTreatment

Argentina, Australia40 locations

Novo Nordisk A/SSponsor

Updated 2026-08-06 · NCT07220642See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Obesity, OverweightCondition

Retatrutide, PlaceboTreatment

Argentina, Canada40 locations

Eli Lilly and CompanySponsor

Updated 2026-07-23 · NCT07035093See eligibility →

Active, not recruitingPhase 3

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

Tirzepatide, PlaceboTreatment

Canada, Czechia33 locations

Eli Lilly and CompanySponsor

Updated 2026-06-29 · NCT06075667See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

Obesity, OverweightCondition

RetatrutideTreatment

Argentina, Canada35 locations

Eli Lilly and CompanySponsor

Updated 2026-06-09 · NCT07357415See eligibility →

Active, not recruitingNot applicable

The Family Stress Study - Chronic Stress and Child Adiposity: Testing a Bio-behavioural Model

Pediatric Obesity, Mental Health Wellness 1Condition

Intervention not listedTreatment

Canada2 locations

University of GuelphSponsor

Updated 2026-06-08 · NCT05534711See eligibility →

Active, not recruitingPhase 3

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Diabetes Mellitus, Type 2Condition

Retatrutide, SemaglutideTreatment

Argentina, Canada77 locations

Eli Lilly and CompanySponsor

Updated 2026-04-13 · NCT06260722See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

ObesityCondition

Retatrutide, PlaceboTreatment

Canada, United Kingdom53 locations

Eli Lilly and CompanySponsor

Updated 2026-03-03 · NCT06859268See eligibility →

Active, not recruitingPhase 3

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

ObesityCondition

Cagrilintide, SemaglutideTreatment

Belgium, Canada36 locations

Novo Nordisk A/SSponsor

Updated 2026-01-20 · NCT06780449See eligibility →

Active, not recruitingPhase 3

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Type 2 Diabetes Mellitus (T2DM), Obesity, OverweightCondition

Maridebart cafraglutide, PlaceboTreatment

Argentina, Bulgaria187 locations

AmgenSponsor

Updated 2025-12-31 · NCT06858878See eligibility →

Active, not recruitingPhase 2

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

Diabetes Mellitus, Type 2, Diabetic Peripheral NeuropathyCondition

CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Treatment

Canada, Denmark54 locations

Novo Nordisk A/SSponsor

Updated 2025-12-05 · NCT06797869See eligibility →

Active, not recruitingPhase 3

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

ObesityCondition

Maridebart Cafraglutide, PlaceboTreatment

Argentina, Australia243 locations

AmgenSponsor

Updated 2025-10-20 · NCT06858839See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Hamilton, Canada

Current studies

Related cities